Comparative Pharmacology
Head-to-head clinical analysis: JENCYCLA versus LEVLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENCYCLA versus LEVLITE.
JENCYCLA vs LEVLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.
Levonorgestrel is a progestin that suppresses ovulation by inhibiting gonadotropin release (LH and FSH) and alters cervical mucus, endometrial thickness, and tubal motility.
1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.
One tablet (levonorgestrel 0.1 mg, ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets.
None Documented
None Documented
8-12 hours; prolonged to 24 hours in severe hepatic impairment
Terminal elimination half-life: 21-28 hours; clinical context: permits once-daily dosing
Renal: 35-45% unchanged; biliary/fecal: 50-60% as metabolites
Renal: ~50% (30% as unchanged drug, 20% as metabolites); Fecal: ~40%; Biliary: minor
Category C
Category C
Oral Contraceptive
Oral Contraceptive